key: cord-0852892-j035k20i authors: Kiss, Z.; Wittmann, I.; Polivka, L.; Surjan, G.; Surjan, O.; Barcza, Z.; Molnar, G. A.; Nagy, D.; Muller, V.; Bogos, K.; Nagy, P.; Kenessey, I.; Weber, A.; Palosi, M.; Szlavik, J.; Schaff, Z.; Szekanecz, Z.; Muller, C.; Kasler, M.; Voko, Z. title: Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines during the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study) date: 2022-03-30 journal: nan DOI: 10.1101/2022.03.27.22273000 sha: 2fea21799e605ca9cb3e82043ff7d0080683ad5e doc_id: 852892 cord_uid: j035k20i Background: In Hungary, the pandemic waves in late 2021 and early 2022 were dominated by the Delta and Omicron SARS-CoV-2 variants, respectively. Booster vaccines were offered with one or two doses for the vulnerable population during these periods. Methods and Findings: The nationwide HUN-VE 2 study examined the effectiveness of primary immunization, single booster, and double booster vaccination in the prevention of Covid-19 related mortality during the Delta and Omicron waves, compared to an unvaccinated control population without prior SARS-CoV-2 infection during the same study periods. The risk of Covid-19 related death was 55% lower during the Omicron vs. Delta wave in the whole study population (n=9,569,648 and n=9,581,927, respectively; rate ratio [RR]: 0.45, 95% confidence interval [CI]: 0.44-0.48). During the Delta wave, the risk of Covid-19 related death was 74% lower in the primary immunized population (RR: 0.26; 95% CI: 0.25-0.28) and 96% lower in the booster immunized population (RR: 0.04; 95% CI: 0.04-0.05), vs. the unvaccinated control group. During the Omicron wave, the risk of Covid-19 related death was 40% lower in the primary immunized population (RR: 0.60; 95% CI: 0.55-0.65) and 82% lower in the booster immunized population (RR: 0.18; 95% CI: 0.16-0.2) vs. the unvaccinated control group. The double booster immunized population had a 93% lower risk of Covid-19 related death compared to those with only one booster dose (RR: 0.07; 95% CI. 0.01-0.46). The benefit of the second booster was slightly more pronounced in older age groups. Conclusions: The HUN-VE 2 study demonstrated the significantly lower risk of Covid-19 related mortality associated with the Omicron vs. Delta variant and confirmed the benefit of single and double booster vaccination against Covid-19 related death. Furthermore, the results showed the additional benefit of a second booster dose in terms of SARS-CoV-2 infection and Covid-19 related mortality. Introduction 60 The first coronavirus disease 2019 (Covid-19) cases were confirmed more than 2 years ago, and 61 several new variants of the SARS-CoV-19 virus have been identified since then (1 available in several countries (9,10). Since August 1, 2021, the Hungarian government recommends 72 heterologous or homologous booster vaccination at least 4 months after the primary vaccination 73 course, particularly for vulnerable patient populations including those aged 60 or older and people 74 with chronic diseases (11). The effectiveness of booster vaccines against SARS-CoV-19 infection 75 after waning vaccine immunity was rapidly demonstrated by a number of studies, however, few 76 analyses reported benefits regarding severe outcomes and death (9,10). By the end of 2021, the new 77 Omicron variant reached Europe, which led to the highest-ever daily infection rates in early 2022 78 with lower mortality rates (12, 13) . In the meantime, certain countries such as Hungary started 79 recommending a second booster shot for the vulnerable population including people aged 60 years or 80 older and those having chronic diseases, however, the fourth dose was available for the whole 81 population (14-16). 82 The aim of the HUN-VE 2 study was to examine the effectiveness of primary immunization as well 83 as first and second booster doses during the Delta and On any day, individuals without any record of SARS-Cov-2 infection at the beginning of each study 107 period were classified as having completed primary immunization if at least 14 days had passed since 108 the administration of the second dose of any vaccine type (or one dose of the Janssen vaccine), 109 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) persons had SARS-CoV-2 infection (3.82%), of whom 6,571 persons died (0.080% of the 137 investigated population) during the study period (Suppl Fig 1) . The average size of the unvaccinated 138 population (without prior SARS-CoV-2 infection) comprised 2,226,526 persons during the Delta 139 wave (27.0% of total), of whom 3,834 (0.172%) died due to Covid-19 ( Figure 2 ). In the total Delta 140 population, the average size of the population with primary immunization was 3,476,436 (42.2%), of 141 whom 2,071 (0.057%) died while having SARS-CoV-2 infection during this study period. 21.1% of 142 this total population received booster immunization, of whom 0.022% (443 persons) died ( Figure 2 ). 143 Mortality rates increased by age, up to 30.38, 13.14, and 2.64 per 100.000 person-days in the oldest 144 age cohort in the non-vaccinated, primary immunized, and booster vaccinated population, 145 respectively. 146 The total study population for the period of the Omicron wave comprised 8,232,169 persons, of 147 whom 2,792 (0.036%) died due to Covid-19. The average size of the primary immunized and booster 148 vaccinated populations was 2,328,562 persons (28.3%) and 3,297,024 (40.05%), respectively (Suppl 149 fig 1) . Of the latter, 66.43% were aged 65 years or older. 31,527 persons (0.38%) had received 150 double booster immunization (mostly a fourth dose, expect for the Janssen vaccine). In the booster 151 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 30, 2022 In the booster immunized population, the risk of Covid-19 related death was 82% lower than in the 238 unvaccinated group, and the few people who had received their second booster dose (n=31,527) had 239 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.27.22273000 doi: medRxiv preprint an almost 100% protection against mortality, with only one Covid-19 related death during the study 240 period. The second booster dose further decreased the rate of SARS-CoV-2 infection by 51% 241 compared to only one booster and provided an additional 93% mortality reduction. Although the 242 short follow-up time of the double booster immunized group and the very low number of patients 243 younger than 65 years in this group limit the interpretation of results related to the effectiveness of 244 the second booster dose, these data confirm the additional short-term benefit of booster doses in the 245 prevention of Covid-19 related mortality during the Omicron wave in the elderly. 246 The strengths of the HUN-VE-2 study include its nationwide nature, and the analysis of vaccine 247 effectiveness during two consecutive waves of the coronavirus pandemic. Furthermore, the large 248 study populations allowed for the evaluation of different levels of vaccination in different age groups. 249 Nevertheless, our study has some limitations. The proportion of undetected cases might have been 250 high and could have increased during the wave dominated by the Omicron variant. Therefore, we 251 refrained from analyzing registered infections. We made an exemption when we estimated the impact 252 of double booster and single booster vaccination, because we wanted to see how much the effect size 253 is different in the case of SARS-CoV-2 infection and Covid-19 related mortality. Although the 254 infection rates might be underestimated, we assume that the ascertainment bias was not likely to 255 significantly affect the relative rates, as the proportion of unregistered cases among all cases was not 256 likely to substantially differ in the two compared groups. 257 We studied the effect of vaccination by age, and adjusted for age when studying total populations, 258 but an important limitation of our study is that we could not adjust for other potential confounders, 259 most importantly for chronic diseases. As chronic diseases represent an indication for early 260 vaccination as well as booster vaccination, and are closely related to mortality, this confounding may 261 have influenced our results to a certain extent. However, as booster and second booster vaccinations 262 were especially recommended for elderly people with chronic diseases, our estimates are 263 conservative. 264 Our study is one of the very few demonstrating the benefit of second booster vaccination. Despite 265 declining effectiveness against symptomatic disease caused by the Omicron variant, booster doses 266 still provided protection against Covid-19 accompanying mortality. This suggests that although 267 antibody responses tend to wane over time (27), cellular immune responses may also play a 268 significant part in the protection against severe outcomes, and this protection may be significantly 269 enhanced by a second booster dose. Our findings also raise the possibility that cellular immune 270 responses may have an important role in the protection against upcoming new SARS-CoV-2 variants. 271 A recent study from Israel demonstrated the rapid decline in the regained reduction of viral load 272 achieved by the booster shot 3-4 months after its administration (30 death. Furthermore, our study is among the first to report the significant additional benefit of a 282 second booster dose in terms of mortality reduction in older populations, beyond the improvement in 283 protection against symptomatic SARS-CoV-2 infection. 284 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Acknowledgments 417 The authors would like to thank Richárd Kiss for the initial data curation and dataset validation. population (B), according to age. *Exact confidence intervals for age-specific mortality rate ratios 425 and Mantel-Haenszel pooled mortality rate ratio for the total population adjusted for age. 426 The datasets generated for this study can be found in the MedRxiv repository. Further inquiries can 438 be directed to the corresponding author. 439 The Covid-19 pandemics led to an immense worldwide burden on healthcare systems, therefore 441 development of vaccines was of high importance. The vaccines were tested in clinical trials against 442 the original strain. However, with time, novel variants such as the alpha, delta and omicron have been 443 arising. The efficacy of Covid-19 vaccines seems to wean over time; therefore, booster vaccines are 444 frequently applied. We report on nationwide efficacy of vaccines in the Hungarian population. We 445 compared the efficacy of first boostered vs. primary vaccinated vs. unvaccinated populations during 446 both Delta and Omicron waves. Moreover, at the time of the Omicron wave, a second booster shot 447 has been made available by the Hungarian government, thus we could also test double booster 448 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.27.22273000 doi: medRxiv preprint vaccinated vs. single booster vaccinated populations. Mortality due to Covid-19 was tested, and we 449 found that primary vaccinated persons were more protected than unvaccinated ones during both 450 waves. The first booster led to an increased efficacy. During the Omicron wave, the second booster 451 provided and additional protection even when compared to the first booster-vaccinated population. 452 Our study provides nationwide data on vaccine efficacy against two variants. As second booster was 453 made available early, data are robust due to a large population. 454 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.27.22273000 doi: medRxiv preprint New Coronavirus Variants are Creating More Challenges to 287 Global Healthcare System: A Brief Report on the Current COVID 19: vaccines, efficacy and effects on variants Nationwide effectiveness of five SARS-CoV-2 vaccines in 293 Effectiveness 297 of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review Vaccines 2022 SARS-CoV-2 vaccine 301 protection and deaths among US veterans during 2021 Waning of BNT162b2 Vaccine Protection 306 against SARS-CoV-2 Infection in Qatar Waning Immunity after the BNT162b2 Vaccine in Israel Effectiveness of mRNA BNT162b2 COVID-19 vaccine 314 up to 6 months in a large integrated health system in the USA: a retrospective cohort study /ATTACHMENT/E998365A-8F41-4C9C-997B-8F5A40D3AAD4/MMC1.PDF 318 Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing 319 severe outcomes in Israel: an observational study Magyarország az első, ahol már a harmadik oltásra is lehet időpontot foglalni Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 329 pandemic Omicron's feeble attack on the lungs could make it less dangerous Introduction of 4th vaccination by the National Public Health Center (NPHC) webpage Attenuated response to fourth dose SARS-CoV-2 339 vaccination in patients with autoimmune disease: a case series 4th Dose COVID mRNA Vaccines' Immunogenicity & Strengthening the Reporting of Observational 347 Studies in Epidemiology (STROBE): Explanation and elaboration Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant Report 50: Hospitalisation risk for Omicron cases 353 in England SUGGESTED CITATION Outcomes of laboratory-confirmed SARS-CoV-2 infection in 356 the Omicron-driven fourth wave compared with previous waves in the Western Cape 357 Province Trends in Disease Severity and Health Care Utilization During 361 the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission 362 Periods -United States Clinical outcomes among 365 patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California SARS-CoV-2 Omicron virus causes attenuated disease in 369 mice and hamsters 371 Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed 372 COVID-19 cases: Systematic review COVID-19) Infection Survey Technical Article: Impact of vaccination on testing 375 positive in the UK -Office for National Statistics Effectiveness of COVID-19 Vaccines 381 against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical 382 Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to 385 immune sera elicited by vaccines after boost SARS-CoV-2 variants dashboard Waning of SARS-CoV-2 booster viral-load reduction effectiveness Zsófia Barcza of Syntesia Medical Communications Ltd. received payment for medical writing 398 support from the National Public Health Center of Hungary. Zoltán Kiss is employed by MSD 399 At the time the study was performed, M.K served as the minister of human resources. The 401 ministry includes the secretariat for health Author Contributions Conceptualization, Methodology, Formal analysis, Validation and Writing -Review & 404 Editing Conceptualization, Methodology, Investigation, Visualization and Writing -Original Draft Formal analysis, Validation, 406 Data curation Investigation and Supervision; Zs Barcza: Writing -Original Draft; GA Molnár: 410 Validation